BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev. 2015;67:389-440. [PMID: 25761609 DOI: 10.1124/pr.114.009472] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Leysen H, Walter D, Clauwaert L, Hellemans L, van Gastel J, Vasudevan L, Martin B, Maudsley S. The Relaxin-3 Receptor, RXFP3, Is a Modulator of Aging-Related Disease. Int J Mol Sci 2022;23:4387. [PMID: 35457203 DOI: 10.3390/ijms23084387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ivell R, Mamsen LS, Andersen CY, Anand-ivell R. Expression and Role of INSL3 in the Fetal Testis. Front Endocrinol 2022;13:868313. [DOI: 10.3389/fendo.2022.868313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Devarakonda T, Mauro AG, Cain C, Das A, Salloum FN. Cardiac Gene Therapy With Relaxin Receptor 1 Overexpression Protects Against Acute Myocardial Infarction. JACC Basic Transl Sci 2022;7:53-63. [PMID: 35128209 DOI: 10.1016/j.jacbts.2021.10.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yokobori K, Kawasaki Y, Sekine Y, Nobusawa S, Sakaki T, Negishi M, Kakizaki S. Androgen receptor phosphorylated at Ser815: The expression and function in the prostate and tumor-derived cells. Biochem Pharmacol 2021;:114794. [PMID: 34715066 DOI: 10.1016/j.bcp.2021.114794] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Wan L, Huang RJ, Luo ZH, Gong JE, Pan A, Manavis J, Yan XX, Xiao B. Reproduction-Associated Hormones and Adult Hippocampal Neurogenesis. Neural Plast 2021;2021:3651735. [PMID: 34539776 DOI: 10.1155/2021/3651735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang J, Lv C, Mo C, Liu M, Wan Y, Li J, Wang Y. Single-Cell RNA Sequencing Analysis of Chicken Anterior Pituitary: A Bird's-Eye View on Vertebrate Pituitary. Front Physiol 2021;12:562817. [PMID: 34267669 DOI: 10.3389/fphys.2021.562817] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Abboud C, Brochoire L, Drouet A, Hossain MA, Hleihel W, Gundlach AL, Landry M. Analgesic effect of central relaxin receptor activation on persistent inflammatory pain in mice: behavioral and neurochemical data. Pain Rep 2021;6:e937. [PMID: 34159282 DOI: 10.1097/PR9.0000000000000937] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz J, Drapkin R, Mes-Masson AM, Rottapel R. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. J Clin Invest 2021;131:142677. [PMID: 33561012 DOI: 10.1172/JCI142677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lin L, Lin G, Zhou Q, Bathgate RAD, Gong GQ, Yang D, Liu Q, Wang MW. Design, synthesis and pharmacological evaluation of tricyclic derivatives as selective RXFP4 agonists. Bioorg Chem 2021;110:104782. [PMID: 33730669 DOI: 10.1016/j.bioorg.2021.104782] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Mallart S, Ingenito R, Bianchi E, Bresciani A, Esposito S, Gallo M, Magotti P, Monteagudo E, Orsatti L, Roversi D, Santoprete A, Tucci F, Veneziano M, Bartsch R, Boehm C, Brasseur D, Bruneau P, Corbier A, Froissant J, Gauzy-Lazo L, Gervat V, Marguet F, Menguy I, Minoletti C, Nicolas MF, Pasquier O, Poirier B, Raux A, Riva L, Janiak P, Strobel H, Duclos O, Illiano S. Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases. J Med Chem 2021;64:2139-50. [PMID: 33555858 DOI: 10.1021/acs.jmedchem.0c01533] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yeom E, Shin H, Yoo W, Jun E, Kim S, Hong SH, Kwon DW, Ryu TH, Suh JM, Kim SC, Lee KS, Yu K. Tumour-derived Dilp8/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3/8 in the brain. Nat Cell Biol 2021;23:172-83. [PMID: 33558728 DOI: 10.1038/s41556-020-00628-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
12 Liu J, Yang K, Jin Y, Liu Y, Chen Y, Zhang X, Yu S, Song E, Chen S, Zhang J, Jing G, An R. H3 relaxin protects against calcium oxalate crystal-induced renal inflammatory pyroptosis. Cell Prolif 2020;53:e12902. [PMID: 32945585 DOI: 10.1111/cpr.12902] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Li HZ, Li N, Shao XX, Liu YL, Xu ZG, Guo ZY. Hydrophobic interactions of relaxin family peptide receptor 3 with ligands identified using a NanoBiT-based binding assay. Biochimie 2020;177:117-26. [PMID: 32810565 DOI: 10.1016/j.biochi.2020.08.008] [Reference Citation Analysis]
14 Ivell R, Alhujaili W, Kohsaka T, Anand-Ivell R. Physiology and evolution of the INSL3/RXFP2 hormone/receptor system in higher vertebrates. Gen Comp Endocrinol 2020;299:113583. [PMID: 32800774 DOI: 10.1016/j.ygcen.2020.113583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hampel U, Chinnery HR, Garreis F, Paulsen F, de Iongh R, Bui BV, Nguyen C, Parry L, Huei Leo C. Ocular Phenotype of Relaxin Gene Knockout (Rln-/-) Mice. Curr Eye Res 2020;45:1211-21. [PMID: 32141786 DOI: 10.1080/02713683.2020.1737714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Suteau V, Briet C, Lebeault M, Gourdin L, Henrion D, Rodien P, Munier M. Human amniotic fluid-based exposure levels of phthalates and bisphenol A mixture reduce INSL3/RXFP2 signaling. Environ Int 2020;138:105585. [PMID: 32126385 DOI: 10.1016/j.envint.2020.105585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Schiffner R, Bischoff SJ, Lehmann T, Irintchev A, Nistor M, Lemke C, Schmidt M. Altered Cerebral Blood Flow and Potential Neuroprotective Effect of Human Relaxin-2 (Serelaxin) During Hypoxia or Severe Hypovolemia in a Sheep Model. Int J Mol Sci 2020;21:E1632. [PMID: 32120997 DOI: 10.3390/ijms21051632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen TY, Li X, Hung CH, Bahudhanapati H, Tan J, Kass DJ, Zhang Y. The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease. Mol Genet Genomic Med 2020;8:e1194. [PMID: 32100955 DOI: 10.1002/mgg3.1194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Huang HN, Pan CY, Su BC, Wu HY, Chen JY. Epinecidin-1 Protects against Methicillin Resistant Staphylococcus aureus Infection and Sepsis in Pyemia Pigs. Mar Drugs 2019;17:E693. [PMID: 31835381 DOI: 10.3390/md17120693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Ang SY, Evans BA, Poole DP, Bron R, DiCello JJ, Bathgate RAD, Kocan M, Hutchinson DS, Summers RJ. INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells. J Mol Endocrinol 2018;60:213-24. [PMID: 29535183 DOI: 10.1530/JME-17-0152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
21 Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J 2019;33:12435-46. [PMID: 31419161 DOI: 10.1096/fj.201901046R] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Leo CH, Jelinic M, Ng HH, Parry LJ, Tare M. Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases. Curr Opin Pharmacol 2019;45:42-8. [PMID: 31048209 DOI: 10.1016/j.coph.2019.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wang J, Nie W, Shao X, Li H, Hu M, Liu Y, Xu Z, Guo Z. Exploring electrostatic interactions of relaxin family peptide receptor 3 and 4 with ligands using a NanoBiT-based binding assay. Biochimica et Biophysica Acta (BBA) - Biomembranes 2019;1861:776-86. [DOI: 10.1016/j.bbamem.2019.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Syreeni A, Sandholm N, Cao J, Toppila I, Maahs DM, Rewers MJ, Snell-Bergeon JK, Costacou T, Orchard TJ, Caramori ML, Mauer M, Klein BEK, Klein R, Valo E, Parkkonen M, Forsblom C, Harjutsalo V, Paterson AD, Groop PH; DCCT/EDIC Research Group., FinnDiane Study Group. Genetic Determinants of Glycated Hemoglobin in Type 1 Diabetes. Diabetes 2019;68:858-67. [PMID: 30674623 DOI: 10.2337/db18-0573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
25 Dschietzig TB. Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials. Mol Cell Endocrinol 2019;487:54-8. [PMID: 30659842 DOI: 10.1016/j.mce.2019.01.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
26 Wang JH, Shao XX, Hu MJ, Liu YL, Xu ZG, Guo ZY. Functionality of an absolutely conserved glycine residue in the chimeric relaxin family peptide R3/I5. Amino Acids 2019;51:619-26. [PMID: 30604098 DOI: 10.1007/s00726-018-02694-y] [Reference Citation Analysis]
27 Valkovic AL, Bathgate RA, Samuel CS, Kocan M. Understanding relaxin signalling at the cellular level. Mol Cell Endocrinol 2019;487:24-33. [PMID: 30592984 DOI: 10.1016/j.mce.2018.12.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ng HH, Esteban-Lopez M, Agoulnik AI. Targeting the relaxin/insulin-like family peptide receptor 1 and 2 with small molecule compounds. Mol Cell Endocrinol 2019;487:40-4. [PMID: 30590098 DOI: 10.1016/j.mce.2018.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Ferlin A, De Toni L, Agoulnik AI, Lunardon G, Armani A, Bortolanza S, Blaauw B, Sandri M, Foresta C. Protective Role of Testicular Hormone INSL3 From Atrophy and Weakness in Skeletal Muscle. Front Endocrinol (Lausanne) 2018;9:562. [PMID: 30323788 DOI: 10.3389/fendo.2018.00562] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
30 Ivell R, Anand-ivell R. Insulin-like peptide 3 (INSL3) is a major regulator of female reproductive physiology. Human Reproduction Update 2018;24:639-51. [DOI: 10.1093/humupd/dmy029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
31 Soubret A, Pang Y, Yu J, Dahlke M. Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects. Br J Clin Pharmacol 2018;84:2572-85. [PMID: 30014598 DOI: 10.1111/bcp.13714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Wang JH, Hu MJ, Zhang L, Shao XX, Lv CH, Liu YL, Xu ZG, Guo ZY. Exploring receptor selectivity of the chimeric relaxin family peptide R3/I5 by incorporating unnatural amino acids. Biochimie 2018;154:77-85. [PMID: 30102931 DOI: 10.1016/j.biochi.2018.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Grampp S, Goppelt-Struebe M. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells. Cell Tissue Res 2018;374:619-27. [PMID: 30078103 DOI: 10.1007/s00441-018-2904-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Thanasupawat T, Glogowska A, Burg M, Krcek J, Beiko J, Pitz M, Zhang GJ, Hombach-Klonisch S, Klonisch T. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma. Mol Oncol 2018;12:1464-79. [PMID: 29949238 DOI: 10.1002/1878-0261.12349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
35 Bathgate RA, Kocan M, Scott DJ, Hossain MA, Good SV, Yegorov S, Bogerd J, Gooley PR. The relaxin receptor as a therapeutic target – perspectives from evolution and drug targeting. Pharmacology & Therapeutics 2018;187:114-32. [DOI: 10.1016/j.pharmthera.2018.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
36 Gaidarov I, Adams J, Frazer J, Anthony T, Chen X, Gatlin J, Semple G, Unett DJ. Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor. Cell Signal 2018;50:9-24. [PMID: 29928987 DOI: 10.1016/j.cellsig.2018.06.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
37 Kosyakova OV, Bespalova ON. Prognostic possibilities of relaxin as a marker of preterm birth. Z akus zen bolezn 2018;67:16-25. [DOI: 10.17816/jowd67216-25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Meadows KL. Ischemic stroke and select adipose-derived and sex hormones: a review. Hormones (Athens) 2018;17:167-82. [PMID: 29876798 DOI: 10.1007/s42000-018-0034-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
39 Schiffner R, Nistor M, Bischoff SJ, Matziolis G, Schmidt M, Lehmann T. Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model. Hypoxia (Auckl) 2018;6:11-22. [PMID: 29862306 DOI: 10.2147/HP.S165092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Hu M, Wang J, Shao X, Liu Y, Xu Z, Guo Z. Overexpression of relaxin family peptide receptor 3 in Escherichia coli and characterization of its ligand binding properties. Process Biochemistry 2018;69:131-5. [DOI: 10.1016/j.procbio.2018.03.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Hu MJ, Shao XX, Li HZ, Nie WH, Wang JH, Liu YL, Xu ZG, Guo ZY. Development of a novel ligand binding assay for relaxin family peptide receptor 3 and 4 using NanoLuc complementation. Amino Acids 2018;50:1111-9. [PMID: 29770870 DOI: 10.1007/s00726-018-2588-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wang JH, Hu MJ, Shao XX, Wei D, Liu YL, Xu ZG, Guo ZY. Cholesterol modulates the binding properties of human relaxin family peptide receptor 3 with its ligands. Arch Biochem Biophys 2018;646:24-30. [PMID: 29601823 DOI: 10.1016/j.abb.2018.03.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Devarakonda T, Salloum FN. Heart Disease and Relaxin: New Actions for an Old Hormone. Trends Endocrinol Metab 2018;29:338-48. [PMID: 29526354 DOI: 10.1016/j.tem.2018.02.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
44 Idrizaj E, Garella R, Francini F, Squecco R, Baccari MC. Relaxin influences ileal muscular activity through a dual signaling pathway in mice. World J Gastroenterol 2018; 24(8): 882-893 [PMID: 29491682 DOI: 10.3748/wjg.v24.i8.882] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Valle Raleigh J, Mauro AG, Devarakonda T, Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A, Salloum FN. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res 2017;113:609-19. [PMID: 28073832 DOI: 10.1093/cvr/cvw246] [Cited by in Crossref: 21] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
46 Venditti M, Donizetti A, Fiengo M, Fasano C, Santillo A, Aniello F, Minucci S. Temporal and spatial expression of insulin-like peptide (insl5a and insl5b) paralog genes during the embryogenesis of Danio rerio. J Exp Zool B Mol Dev Evol 2018;330:33-40. [PMID: 29319231 DOI: 10.1002/jez.b.22787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Nistor M, Schmidt M, Schiffner R. The relaxin peptide family - potential future hope for neuroprotective therapy? A short review. Neural Regen Res 2018;13:402-5. [PMID: 29623915 DOI: 10.4103/1673-5374.228713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 de Ávila C, Chometton S, Lenglos C, Calvez J, Gundlach AL, Timofeeva E. Differential effects of relaxin-3 and a selective relaxin-3 receptor agonist on food and water intake and hypothalamic neuronal activity in rats. Behavioural Brain Research 2018;336:135-44. [DOI: 10.1016/j.bbr.2017.08.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
49 Boccalini G, Sassoli C, Bani D, Nistri S. Relaxin induces up-regulation of ADAM10 metalloprotease in RXFP1-expressing cells by PI3K/AKT signaling. Mol Cell Endocrinol 2018;472:80-6. [PMID: 29180109 DOI: 10.1016/j.mce.2017.11.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
50 Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 2017;16:829-42. [PMID: 29075003 DOI: 10.1038/nrd.2017.178] [Cited by in Crossref: 875] [Cited by in F6Publishing: 962] [Article Influence: 175.0] [Reference Citation Analysis]
51 Baheti S, Singh P, Zhang Y, Evans J, Jensen MD, Somers VK, Kocher JA, Sun Z, Chakkera HA. Adipose tissue DNA methylome changes in development of new-onset diabetes after kidney transplantation. Epigenomics 2017;9:1423-35. [PMID: 28967791 DOI: 10.2217/epi-2017-0050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Wu F, Song G, de Graaf C, Stevens RC. Structure and Function of Peptide-Binding G Protein-Coupled Receptors. J Mol Biol 2017;429:2726-45. [PMID: 28705763 DOI: 10.1016/j.jmb.2017.06.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
53 Wetzl V, Schinner E, Kees F, Faerber L, Schlossmann J. Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination. Naunyn Schmiedebergs Arch Pharmacol 2017;390:939-48. [PMID: 28660304 DOI: 10.1007/s00210-017-1394-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
54 Schiffner R, Reiche J, Schmidt M, Jung C, Walther S, Irintchev A, Bischoff SJ. Pulmonary arterial compliance and pulmonary hemodynamic effects of Serelaxin in a sheep model. CH 2017;66:219-29. [DOI: 10.3233/ch-170269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wang J, Shao X, Hu M, Wei D, Nie W, Liu Y, Xu Z, Guo Z. Rapid preparation of bioluminescent tracers for relaxin family peptides using sortase-catalysed ligation. Amino Acids 2017;49:1611-7. [DOI: 10.1007/s00726-017-2455-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
56 Bruell S, Sethi A, Smith N, Scott DJ, Hossain MA, Wu QP, Guo ZY, Petrie EJ, Gooley PR, Bathgate RAD. Distinct activation modes of the Relaxin Family Peptide Receptor 2 in response to insulin-like peptide 3 and relaxin. Sci Rep 2017;7:3294. [PMID: 28607406 DOI: 10.1038/s41598-017-03638-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
57 Wei D, Hu MJ, Shao XX, Wang JH, Nie WH, Liu YL, Xu ZG, Guo ZY. Development of a selective agonist for relaxin family peptide receptor 3. Sci Rep 2017;7:3230. [PMID: 28607363 DOI: 10.1038/s41598-017-03465-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
58 Dai Y, Ivell R, Liu X, Janowski D, Anand-Ivell R. Relaxin-Family Peptide Receptors 1 and 2 Are Fully Functional in the Bovine. Front Physiol 2017;8:359. [PMID: 28634453 DOI: 10.3389/fphys.2017.00359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
59 Kaftanovskaya EM, Soula M, Myhr C, Ho BA, Moore SN, Yoo C, Cervantes B, How J, Marugan J, Agoulnik IU, Agoulnik AI. Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290. J Endocr Soc 2017;1:712-25. [PMID: 28825052 DOI: 10.1210/js.2017-00112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
60 Ivell R, Agoulnik AI, Anand-Ivell R. Relaxin-like peptides in male reproduction - a human perspective. Br J Pharmacol 2017;174:990-1001. [PMID: 27933606 DOI: 10.1111/bph.13689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
61 Kania A, Gugula A, Grabowiecka A, de Ávila C, Blasiak T, Rajfur Z, Lewandowski MH, Hess G, Timofeeva E, Gundlach AL, Blasiak A. Inhibition of oxytocin and vasopressin neuron activity in rat hypothalamic paraventricular nucleus by relaxin-3-RXFP3 signalling. J Physiol 2017;595:3425-47. [PMID: 28098344 DOI: 10.1113/JP273787] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
62 Wang JH, Shao XX, Hu MJ, Wei D, Liu YL, Xu ZG, Guo ZY. A novel BRET-based binding assay for interaction studies of relaxin family peptide receptor 3 with its ligands. Amino Acids 2017;49:895-903. [PMID: 28161795 DOI: 10.1007/s00726-017-2387-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
63 Unemori E. Serelaxin in clinical development: past, present and future. Br J Pharmacol 2017;174:921-32. [PMID: 28009437 DOI: 10.1111/bph.13695] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
64 Shen L, Lin Y, Sun Z, Yuan X, Chen L, Shen B. Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers. Sci Rep 2016;6:39663. [PMID: 28000768 DOI: 10.1038/srep39663] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
65 Agoulnik AI, Agoulnik IU, Hu X, Marugan J. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol 2017;174:977-89. [PMID: 27771940 DOI: 10.1111/bph.13656] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
66 Ang SY, Hutchinson DS, Evans BA, Hossain MA, Patil N, Bathgate RA, Kocan M, Summers RJ. The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4. Naunyn Schmiedebergs Arch Pharmacol 2017;390:105-11. [PMID: 27888281 DOI: 10.1007/s00210-016-1321-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
67 Leo CH, Jelinic M, Ng HH, Marshall SA, Novak J, Tare M, Conrad KP, Parry LJ. Vascular actions of relaxin: nitric oxide and beyond. Br J Pharmacol. 2017;174:1002-1014. [PMID: 27590257 DOI: 10.1111/bph.13614] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
68 Marshall SA, Senadheera SN, Parry LJ, Girling JE. The Role of Relaxin in Normal and Abnormal Uterine Function During the Menstrual Cycle and Early Pregnancy. Reprod Sci 2017;24:342-54. [DOI: 10.1177/1933719116657189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
69 Nascimento AR, Macheroni C, Lucas TF, Porto CS, Lazari MF. Crosstalk between FSH and relaxin at the end of the proliferative stage of rat Sertoli cells. Reproduction 2016;152:613-28. [PMID: 27601715 DOI: 10.1530/REP-16-0330] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
70 Park SE, Lim SR, Choi H, Bae J. Triazine herbicides inhibit relaxin signaling and disrupt nitric oxide homeostasis. Toxicology and Applied Pharmacology 2016;307:10-8. [DOI: 10.1016/j.taap.2016.07.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
71 Liu Y, Zhang L, Shao XX, Hu MJ, Liu YL, Xu ZG, Guo ZY. A negatively charged transmembrane aspartate residue controls activation of the relaxin-3 receptor RXFP3. Arch Biochem Biophys 2016;604:113-20. [PMID: 27353281 DOI: 10.1016/j.abb.2016.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Klonisch T, Glogowska A, Thanasupawat T, Burg M, Krcek J, Pitz M, Jaggupilli A, Chelikani P, Wong GW, Hombach-Klonisch S. Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells. Br J Pharmacol 2017;174:1025-33. [PMID: 27443788 DOI: 10.1111/bph.13559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
73 Pintalhao M, Castro‐chaves P, Vasques‐novoa F, Gonçalves F, Mendonça L, Fontes‐carvalho R, Lourenço P, Almeida P, Leite‐moreira A, Bettencourt P. Relaxin serum levels in acute heart failure are associated with pulmonary hypertension and right heart overload. Eur J Heart Fail 2017;19:218-25. [DOI: 10.1002/ejhf.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
74 Wetzl V, Schinner E, Kees F, Hofmann F, Faerber L, Schlossmann J. Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin. Front Pharmacol 2016;7:195. [PMID: 27462268 DOI: 10.3389/fphar.2016.00195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
75 Sarwar M, Du XJ, Dschietzig TB, Summers RJ. The actions of relaxin on the human cardiovascular system. Br J Pharmacol 2017;174:933-49. [PMID: 27239943 DOI: 10.1111/bph.13523] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
76 Hu MJ, Shao XX, Wang JH, Wei D, Guo YQ, Liu YL, Xu ZG, Guo ZY. Mechanism for insulin-like peptide 5 distinguishing the homologous relaxin family peptide receptor 3 and 4. Sci Rep 2016;6:29648. [PMID: 27404393 DOI: 10.1038/srep29648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
77 Bischoff SJ, Schmidt M, Lehmann T, Irintchev A, Schubert H, Jung C, Schwab M, Huber O, Matziolis G, Schiffner R. Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model. Am J Physiol Heart Circ Physiol 2016;311:H613-20. [PMID: 27402664 DOI: 10.1152/ajpheart.00118.2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
78 Ferlin A, De Toni L, Sandri M, Foresta C. Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside. Br J Pharmacol 2017;174:1015-24. [PMID: 27059798 DOI: 10.1111/bph.13490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
79 Leo CH, Jelinic M, Ng HH, Tare M, Parry LJ. Serelaxin: A Novel Therapeutic for Vascular Diseases. Trends Pharmacol Sci 2016;37:498-507. [PMID: 27130518 DOI: 10.1016/j.tips.2016.04.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
80 Sethi A, Bruell S, Patil N, Hossain MA, Scott DJ, Petrie EJ, Bathgate RAD, Gooley PR. The complex binding mode of the peptide hormone H2 relaxin to its receptor RXFP1. Nat Commun 2016;7:11344. [PMID: 27088579 DOI: 10.1038/ncomms11344] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
81 Liu Y, Guo Z. Novel bioluminescent binding assays for interaction studies of protein/peptide hormones with their receptors. Amino Acids 2016;48:1151-60. [DOI: 10.1007/s00726-016-2220-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
82 Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA, Agoulnik IU, Ferrer M, Marugan JJ, Southall N, Agoulnik AI. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry 2016;55:1772-83. [PMID: 26866459 DOI: 10.1021/acs.biochem.5b01195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
83 Petrie EJ, Lagaida S, Sethi A, Bathgate RA, Gooley PR. In a Class of Their Own - RXFP1 and RXFP2 are Unique Members of the LGR Family. Front Endocrinol (Lausanne) 2015;6:137. [PMID: 26441827 DOI: 10.3389/fendo.2015.00137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
84 Kocan M, Ang SY, Summers RJ. Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3. Neurochem Res 2016;41:610-9. [PMID: 26294284 DOI: 10.1007/s11064-015-1701-3] [Reference Citation Analysis]
85 Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne) 2015;6:128. [PMID: 26347712 DOI: 10.3389/fendo.2015.00128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
86 Thanasupawat T, Glogowska A, Burg M, Wong GW, Hoang-Vu C, Hombach-Klonisch S, Klonisch T. RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer. Front Endocrinol (Lausanne) 2015;6:127. [PMID: 26322020 DOI: 10.3389/fendo.2015.00127] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]